CL2019003924A1 - Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485). - Google Patents

Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).

Info

Publication number
CL2019003924A1
CL2019003924A1 CL2019003924A CL2019003924A CL2019003924A1 CL 2019003924 A1 CL2019003924 A1 CL 2019003924A1 CL 2019003924 A CL2019003924 A CL 2019003924A CL 2019003924 A CL2019003924 A CL 2019003924A CL 2019003924 A1 CL2019003924 A1 CL 2019003924A1
Authority
CL
Chile
Prior art keywords
functional capacity
pridopidine
treatment
divisional application
functional decline
Prior art date
Application number
CL2019003924A
Other languages
English (en)
Inventor
Michael Hayden
Spyridon Papapetropoulos
Juha-Matti Savola
Eli Eyal
Beth Borowsky
Igor D Grachev
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of CL2019003924A1 publication Critical patent/CL2019003924A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Abstract

ESTA INVENCIÓN PROPORCIONA UN MÉTODO PARA MANTENER LA CAPACIDAD FUNCIONAL, MEJORAR LA CAPACIDAD FUNCIONAL O RETARDAR LA DISMINUCIÓN DE LA CAPACIDAD FUNCIONAL EN UN PACIENTE HUMANO ADMINISTRANDO PERIÓDICAMENTE POR VÍA ORAL UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE PRIDOPIDINA QUE SE ADMINISTRA EN UNA DOSIS DE 90-225 MG AL PACIENTE POR DÍA, PARA MANTENER ASÍ LA CAPACIDAD FUNCIONAL, MEJORAR LA CAPACIDAD FUNCIONAL O RETARDAR LA DISMINUCIÓN DE LA CAPACIDAD FUNCIONAL EN EL PACIENTE HUMANO.
CL2019003924A 2016-08-24 2019-12-31 Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485). CL2019003924A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US201662416685P 2016-11-02 2016-11-02

Publications (1)

Publication Number Publication Date
CL2019003924A1 true CL2019003924A1 (es) 2020-05-29

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000485A CL2019000485A1 (es) 2016-08-24 2019-02-22 Uso de pridopidina para el tratamiento de la disminución funcional.
CL2019003924A CL2019003924A1 (es) 2016-08-24 2019-12-31 Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019000485A CL2019000485A1 (es) 2016-08-24 2019-02-22 Uso de pridopidina para el tratamiento de la disminución funcional.

Country Status (11)

Country Link
US (1) US11207310B2 (es)
EP (1) EP3504187A4 (es)
JP (2) JP6912574B2 (es)
CN (2) CN109923102B (es)
AU (2) AU2017315783C1 (es)
BR (1) BR112019003732A2 (es)
CA (2) CA3151507A1 (es)
CL (2) CL2019000485A1 (es)
IL (1) IL311081A (es)
MX (2) MX2019002265A (es)
WO (1) WO2018039477A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
MX2015017307A (es) 2013-06-21 2016-08-03 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
JP7278210B2 (ja) * 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
PE20190979A1 (es) 2016-09-15 2019-07-09 Boehringer Ingelheim Int Compuestos de heteroarilcarboxamida como inhibidores de ripk2
JP2020533296A (ja) 2017-09-08 2020-11-19 プリレニア ニューロセラピューティクス リミテッド 薬物誘発性ジスキネジアを治療するためのプリドピジン
BR112021024744A2 (pt) * 2019-06-12 2022-03-22 Prilenia Neurotherapeutics Ltd Método para melhorar, manter ou reduzir o comprometimento da capacidade funcional e função motora de um paciente humano com doença de huntington
AU2021266476A1 (en) * 2020-05-04 2022-11-24 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective S1R agonist

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
WO2005053703A1 (en) 2003-12-02 2005-06-16 Leslie James Sheldon Combination therapy for dementia, depression and apathy
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
CN101056854B (zh) 2004-10-13 2013-06-05 Nsab神经研究瑞典公司分公司 合成4-(3-甲磺酰基苯基)-1-n-丙基-哌啶的方法
PE20071092A1 (es) 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
AU2008239841B2 (en) 2007-04-12 2013-07-18 Teva Pharmaceuticals International Gmbh N-oxide and/or di-N-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US8669048B2 (en) 2008-06-24 2014-03-11 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
ES2804779T3 (es) 2009-09-24 2021-02-09 Capsugel Belgium Nv Cápsulas resistentes a los ácidos
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
US20130197031A1 (en) 2010-09-03 2013-08-01 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
EP2710041A4 (en) 2011-05-18 2014-11-05 Parkinson S Inst ASSAY FOR DETERMINING LRRK2 ACTIVITY IN MORBUS PARKINSON
JP6189299B2 (ja) 2011-09-07 2017-08-30 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー プリドピジン塩酸塩の新規な多形形態
US9012476B2 (en) 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CN104470585A (zh) 2012-04-04 2015-03-25 爱华克斯国际有限公司 用于联合疗法的药物组合物
US20150209346A1 (en) 2012-09-27 2015-07-30 Teva Pharmaceutical Industries, Ltd. Combination of laquinimod and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
AU2013323133A1 (en) 2012-09-27 2015-05-07 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular Huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
MX2015017307A (es) 2013-06-21 2016-08-03 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
EP3096759B1 (en) 2014-01-22 2022-04-06 Prilenia Neurotherapeutics Ltd. Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
JP6887952B2 (ja) 2015-02-25 2021-06-16 プリレニア ニューロセラピューティクス リミテッド 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
JP7278210B2 (ja) 2016-08-24 2023-05-19 プリレニア ニューロセラピューティクス リミテッド ジストニアを治療するためのプリドピジンの使用
CA3036842A1 (en) 2016-09-15 2018-03-22 Prilenia Therapeutics Development Ltd. Use of pridopidine for the treatment of anxiety and depression
CN109982686A (zh) 2016-09-16 2019-07-05 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗rett综合征的用途
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
BR112019015000A2 (pt) 2017-01-20 2020-04-07 Agency Science Tech & Res uso de pridopidina para o tratamento da síndrome do x frágil
JP7082186B2 (ja) 2017-08-14 2022-06-07 プリレニア ニューロセラピューティクス リミテッド プリドピジンによる筋萎縮性側索硬化症の治療方法
CN111278431A (zh) 2017-08-30 2020-06-12 普瑞尼亚神经治疗有限公司 普利多匹定的高浓度剂型

Also Published As

Publication number Publication date
US11207310B2 (en) 2021-12-28
AU2017315783C1 (en) 2020-12-24
CN115671103A (zh) 2023-02-03
EP3504187A1 (en) 2019-07-03
CL2019000485A1 (es) 2019-07-12
AU2020223736B2 (en) 2022-04-07
CN109923102B (zh) 2022-11-15
CA3035092C (en) 2022-05-31
US20180055832A1 (en) 2018-03-01
WO2018039477A1 (en) 2018-03-01
IL311081A (en) 2024-04-01
EP3504187A4 (en) 2020-05-06
MX2019002265A (es) 2019-10-30
AU2020223736A1 (en) 2020-09-17
JP6912574B2 (ja) 2021-08-04
CA3035092A1 (en) 2018-03-01
BR112019003732A2 (pt) 2020-02-18
CN109923102A (zh) 2019-06-21
CA3151507A1 (en) 2018-03-01
JP2021119186A (ja) 2021-08-12
AU2017315783A1 (en) 2019-04-11
MX2022003072A (es) 2022-06-17
JP2019524898A (ja) 2019-09-05
AU2017315783B2 (en) 2020-05-28
NZ751156A (en) 2021-01-29

Similar Documents

Publication Publication Date Title
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
PE20160195A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
NI201100147A (es) Métodos para tratar infartos agudos de miocardio y trastornos relacionados.
PH12015502628A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
ECSP088874A (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
DK1891038T3 (da) Substituerede n-arylpyrrolidiner som selektive androgenreceptormodulatorer
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
UY30901A (es) Nuevos metodos
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CL2019003533A1 (es) Uso de vibegron para tratar vejiga sobreactiva.
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
CL2004000984A1 (es) Forma de dosificacion oral de una sal de magnesio de (s)-pantopazol, para la profilaxis o tratamiento de una condicion asociada a inhibir la bomba protonica.
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
AR108792A1 (es) Composiciones que comprenden timolol
EA201990553A1 (ru) Применение придопидина для лечения ухудшения функциональной способности
EA202190247A1 (ru) ПРИМЕНЕНИЕ рГЦ СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
BR112023024085A2 (pt) Composto usado como inibidor de bcr-abl